163 related articles for article (PubMed ID: 25158928)
1. Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor-alpha Inhibitors.
Deepak P; Stobaugh DJ
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1857-8. PubMed ID: 25158928
[No Abstract] [Full Text] [Related]
2. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
4. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Ertz-Archambault N; Kosiorek H; Taylor GE; Kelemen K; Dueck A; Castro J; Marino R; Gauthier S; Finn L; Sproat LZ; Palmer J; Mesa RA; Al-Kali A; Foran J; Tibes R
JAMA Oncol; 2017 Jul; 3(7):936-943. PubMed ID: 28152123
[TBL] [Abstract][Full Text] [Related]
5. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
6. Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease.
Marshall JK; Otley AR; Afif W; Bernstein CN; Hookey L; Leontiadis G; Panaccione R; Bressler B;
Can J Gastroenterol Hepatol; 2014; 28(7):371-2. PubMed ID: 25157527
[No Abstract] [Full Text] [Related]
7. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
Lopez A; Beaugerie L; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2014 Dec; 10(12):1563-5. PubMed ID: 25362886
[TBL] [Abstract][Full Text] [Related]
8. The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
Ha C
Am J Gastroenterol; 2021 Apr; 116(4):671-672. PubMed ID: 33982934
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine side effects in the treatment of chronic inflammatory bowel disease.
González Lara V; Pérez Calle JL
Rev Esp Enferm Dig; 2001 Dec; 93(12):765-8. PubMed ID: 11995358
[No Abstract] [Full Text] [Related]
10. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
Kim JH; Kim JW
Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953
[TBL] [Abstract][Full Text] [Related]
11. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
12. Thiopurines best practice.
Friedman A
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():6-7. PubMed ID: 26990458
[No Abstract] [Full Text] [Related]
13. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy.
Hutson JR; Matlow JN; Moretti ME; Koren G
J Obstet Gynaecol; 2013 Jan; 33(1):1-8. PubMed ID: 23259868
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of inflammatory bowel disease.
van den Bosch BJ; Coenen MJ
Pharmacogenomics; 2021 Jan; 22(1):55-66. PubMed ID: 33305616
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
[No Abstract] [Full Text] [Related]
16. Azathioprine: association with therapy-related myelodysplastic syndrome and acute myeloid leukemia.
Kwong YL
J Rheumatol; 2010 Mar; 37(3):485-90. PubMed ID: 20080917
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia after 10 years of azathioprine treatment for Crohn's disease.
Nouha T; Asma M; Nadia B; Emna BM; Yosra Z; Yosra S
Int J Clin Pharmacol Ther; 2023 Nov; 61(11):520-524. PubMed ID: 37548454
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines.
Teruel C; López-San Román A; Bermejo F; Taxonera C; Pérez-Calle JL; Gisbert JP; Martín-Arranz M; Ponferrada A; Van Domselaar M; Algaba A; Estellés J; López-Serrano P; Linares PM; Muriel A
Am J Gastroenterol; 2010 Sep; 105(9):2003-8. PubMed ID: 20700117
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine-induced acute pancreatitis in inflammatory bowel disease : natural history and severity spectrum.
Peixoto A; Pinto ER; Silva M; Coelho R; Santos-Antunes J; Andrade P; Gaspar R; Nunes A; Lopes S; Macedo G
Acta Gastroenterol Belg; 2017; 80(1):87-88. PubMed ID: 29364109
[No Abstract] [Full Text] [Related]
20. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
